Limonin ameliorates ulcerative colitis by regulating STAT3/miR-214 signaling pathway.


Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 17 02 2019
revised: 08 07 2019
accepted: 17 07 2019
pubmed: 6 8 2019
medline: 15 2 2020
entrez: 6 8 2019
Statut: ppublish

Résumé

Ulcerative colitis (UC) is a major inflammatory bowel disease (IBD) which has become a global public health problem. Limonin is a triterpenoid extracted from citrus which possesses the capacities to against inflammations and cell apoptosis. However, the efficacy and the underlying mechanisms of limonin in the treatment of UC remain unclear. In this study, we first investigated the therapeutic effects of limonin on dextran sodiumsulfate (DSS)-induced UC in vivo by examining the changes of disease activity index (DAI), the colon length, the colon histology, and cyto/chemokine levels. We found that limonin markedly reduced DAI, intestinal damages, and the levels of pro-inflammatory cytokines, such as TNF-α and IL-6. In vitro, limonin significantly repressed the productions of pro-inflammatory cytokines in cultured normal colonic epithelial cells. Mechanistically, we demonstrated that limonin improved the prognosis of UC mainly through downregulating p-STAT3/miR-214 levels. Collectively, our results suggested that limonin was a novel therapeutic agent and it was expected to be translated into the clinic to improve the prognosis of UC.

Identifiants

pubmed: 31382166
pii: S1567-5769(19)30354-6
doi: 10.1016/j.intimp.2019.105768
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents 0
IL10 protein, mouse 0
Interleukin-6 0
Limonins 0
MicroRNAs 0
Mirn214 microRNA, mouse 0
STAT3 Transcription Factor 0
Stat3 protein, mouse 0
interleukin-6, mouse 0
Interleukin-10 130068-27-8
Dextran Sulfate 9042-14-2
limonin L0F260866S

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105768

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Shijia Liu (S)

The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China.

Shufang Zhang (S)

Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, Jiangsu 210009, China.

Xiangyu Lv (X)

Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, Jiangsu 210009, China.

Jiawei Lu (J)

State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu 210009, China.

Cong Ren (C)

Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, Jiangsu 210009, China.

Zhiqin Zeng (Z)

Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, Jiangsu 210009, China.

Lufeng Zheng (L)

Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, Jiangsu 210009, China.

Xianke Zhou (X)

State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.

Haiyan Fu (H)

State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China. Electronic address: hy_fu426@126.com.

Dong Zhou (D)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, United States. Electronic address: zhoudong@pitt.edu.

Yugen Chen (Y)

The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China. Electronic address: 13951672230@163.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH